Collagen metabolism markers as a reflection of bone and soft tissue turnover during the menstrual cycle and oral contraceptive use.

Two different groups of women, 23 healthy young adults and 13 women with chronic posterior pelvic pain, were studied before and during use of oral contraceptives (OC). Collagen metabolism markers-here, the amino-terminal propeptide of type I procollagen, the carboxy-terminal telopeptide of type I collagen, and the amino-terminal of procollagen type III-as well as hormones and other endocrine factors indicating the balance between androgen expression/anabolism and catabolism of the subjects (testosterone, sex-hormone binding globulin, and insulin-like growth factor I were measured. Type I procollagen, the carboxy-terminal telopeptide of type I collagen, and the amino-terminal of procollagen type III were all significantly decreased during OC use.

Oral contraceptives and back pain in women in a Swedish community.

Background: Female back pain is a clinical problem-especially low back pain with symptoms from the pelvic posterior region-that is often aggravated in connection with pregnancy and childbirth. Hormones have been suggested as an aetiologic factor. This study is aimed to determine whether additional hormone preparations, i.

A multicenter randomized controlled trial of injections of sterile water and saline for chronic myofascial pain syndromes.

A randomised controlled trial was used to test the hypothesis that cutaneous injections of sterile water (SWI) have no benefit over saline (PSI) as a method of pain reduction among patients with myofascial pain syndromes. Six general practitioners located at 6 different clinics of general practice treated 117 patients (91 female, 26 male, aged > or = 25 years) with myofascial pain syndrome for at least 3 months in one or both of the upper quadrants of the body. Patients were randomised to receive either SWI or PSI which was administered sub- and intracutaneously on 1 occasion.

Serum levels of relaxin during the menstrual cycle and oral contraceptive use.

Serum relaxin levels were analysed in 12 healthy women every other day during the menstrual cycle and during a second cycle on oral contraceptives. Relaxin levels in 7 women with posterior pelvic and lumbar pain were also measured. Relaxin was detected during both the follicular and luteal phases of the menstrual cycle in some of the healthy women.